Showing results (241-250 of 504) with videos related to
Sort By:
Pageof 51
Leukemia Research Reports|September 22, 2025
First reported TRIB1 copy number loss in myelodysplastic syndrome (MDS) revealed by single nucleotide polymorphism array (SNP-array) with patient-matched controlKun Chi, Lili SongLeukemia Research Reports|December 23, 2020
Prognostic impact of peripheral blood Wilms' tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysisTomoya Maeda, Akira Matsuda, Chie Asou, et al.Leukemia Research Reports|December 30, 2020
Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1Asako Takeuchi, Toshinori Kondo, Taizo Tasaka, et al.Leukemia Research Reports|December 24, 2019
Genotypic and phenotypic evolution in a patient with chronic myelomonocytic leukemiaKlaus Geissler, Eva Jäger, Michael GurbiszLeukemia Research Reports|December 24, 2019
Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administrationMary Nauffal, Lillian Werner, Jian Ni, et al.Leukemia Research Reports|December 24, 2019
Association of genes ARID5B, CEBPE and folate pathway with acute lymphoblastic leukemia in a population from the Brazilian Amazon regionDarlen Cardoso Carvalho, Alayde Vieira Wanderley, Fernando Augusto Rodrigues Mello Junior, et al.Leukemia Research Reports|March 27, 2020
The acquisition of trisomy 8 associated with Behçet's-like disease in myelodysplastic syndromeSatoko Oka, Kazuo Ono, Masaharu NohgawaLeukemia Research Reports|June 11, 2021
Post-transplant relapse of therapy-related MDS as gastric myeloid sarcoma: Case report and review of literatureAmy Song, Masoumeh Ghayouri, Farhan Hiya, et al.Leukemia Research Reports|October 21, 2020
Even mild hemolysis in paroxysmal nocturnal hemoglobinuria could severely compromise the quality of life due to long-term sustained intolerant fatigueKazuya SakaiLeukemia Research Reports|February 24, 2022
Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapyJames W Day, Thomas A Fox, Rajeev Gupta, et al.Pageof 51